Summary
Murine monoclonal antibodies (MCAs) against human ovarian tumor associated antigen NB/70K have been prepared. One of these MCAs, NB12123, was chosen for the development of a radioimmunoassay for measuring serum NB/70K levels. In this assay, the average NB/70K level in 75 normal, healthy controls was 11.9 activity units (AU) with an SD of 14.9 AU. The normal cut off value for this assay was set at 45 AU (mean +2 SD). 24 of 46 (52%) ovarian cancer patients, 7 of 18 (39%) patients with benign ovarian cysts or tumors and 3 of 85 (4%) control samples had elevated serum NB/70K levels. Comparison of NB/70K levels measured in the NB12123 assay with levels measured in an assay using a polyclonal antiNB/70K previously developed in our laboratory [13] indicated that although both assays had approximately the same percentage of positive ovarian cancer patient samples, there appeared to be no correlation between the absolute NB/70K levels measured by the two assays. The rank of ovarian cancer patient samples was also different for the two assays. Also, almost 40% of patients with benign ovarian cysts and tumors had elevated serum NB/70K levels as measured by the NB12123 assay as compared to 0% for the polyclonal assay. Reciprocal cross-blocking experiments, absorption studies, and immune precipitate analysis indicated that both the monoclonal NB12123 assay and the polyclonal antiNB/70K assay measured the same population of NB/70K molecules. However, the polyclonal antibody recognizes epitopes in addition to that recognized by NB12123. Taken together, these results suggest that the epitope recognized by NB12123 is not as specific for malignant ovarian tumors as the epitope(s) recognized by polyclonal antiNB/70K and/or that more than the one epitope detected by the MCA is responsible for the specificity for ovarian cancer of the polyclonal NB/70K assay. In spite of this, the greater sensitivity and range of the monoclonal NB12123 assay make it possible to monitor serum NB/70K levels in ovarian cancer patients. In four patients examined, the fluctuating serum NB/70K levels appeared to correlate well with clinical status
Similar content being viewed by others
References
Bast RC, Fenney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
Bast Jr RC, Klug TL, St. John E, Jenisen E, Niloff J, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887
Bhattacharya M, Chatterjee SK, Barlow JJ (1984) Production and characterization of monoclonal antibody to a 60Kd glycoprotein in ovarian carcinoma. Proc Am Assoc Cancer Res 25:248
Bizzari JP, MacKillop WJ, Buick RN (1983) Cellular specificity of NB/70K, a putative human ovarian tumor antigen. Cancer Res 43:846–847
Chang P-L, Urbach GI, Dembo AJ (1984) Circulating levels of ovarian cancer antigen NB/70K: Clinical correlations. Proc Am Soc Clin Oncol 3:2
Greenwood FC, Hunter WM, Glover JS (1963) The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 89:114–123
Harwell LW, Bolognino M, Bidlack JM, Knapp RJ, Lord EM (1984) A freezing method for cell fusions to distribute and reduce labor and permit more thorough early evaluation of hybridomas. J Immunol Methods 66:59–67
Kabawat SE, Bast Jr RC, Bhan AK, Welch WR, Knapp RC, Colvin RB (1983) Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2:275–285
Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB (1983) Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79:98–104
Knauf S, Urbach GI (1981) Identification, purification and radioimmunoassay of NB/70K, a human ovarian tumor-associated antigen. Cancer Res 41:1351–1357
Knauf S, Beecham J (1982) Inhibitory factor (IF) in ovarian cancer patient ascitic fluid interferes with binding of antibody to tumor antigen NB/70K. Proc Fed Am Soc Exper Biol 41:43
Knauf S, Taillon-Miller P. An improved radioimmunoassay for human ovarian tumor antigen NB/70K. Gynecol Oncol (in press)
Knauf S, Taillon-Miller P, Helmkamp BF, Bonfiglio TA, Beecham JB (1984) Selectivity for ovarian cancer of an improved serum radioimmunoassay for human ovarian tumor-associated antigen NB/70K. Gynecol Oncol 17:349–355
Author information
Authors and Affiliations
Additional information
Supported in part by ACS # PDT 231 and a grant from the Elsa U. Pardee Foundation
Rights and permissions
About this article
Cite this article
Knauf, S., Kalwas, J., Helmkamp, B.F. et al. Monoclonal antibodies against human ovarian tumor associated antigen NB/70K: Preparation and use in a radioimmunoassay for measuring NB/70K in serum. Cancer Immunol Immunother 21, 217–225 (1986). https://doi.org/10.1007/BF00199365
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199365